Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
// Maryam Zanjirband 1 , Richard J. Edmondson 2 , John Lunec 1 1 Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne NE2 4HH, United Kingdom 2 Faculty Institute for Cancer Sciences, University of Manchester, Manchester M13 9WL, United Kingdom Correspondence to: John Lunec, email: john.lunec@ncl.ac.uk Keywords: ovarian cancer, MDM2-p53 antagonists, Nutlin-3/RG7388, p53, combined treatment Received: March 22, 2016 Accepted: April 26, 2016 Published: May 20, 2016 ABSTRACT Ovarian cancer is the fifth leading cause of cancer-related female deaths. Due to serious side effects, relapse and resistance to standard chemotherapy, better and more targeted approaches are required. Mutation of the TP53 gene accounts for 50% of all human cancers. In the remaining malignancies, non-genotoxic activation of wild-type p53 by small molecule inhibition of the MDM2-p53 binding interaction is a promising therapeutic strategy. Proof of concept was established with the cis-imidazoline Nutlin-3, leading to the development of RG7388 and other compounds currently in early phase clinical trials. This preclinical study evaluated the effect of Nutlin-3 and RG7388 as single agents and in combination with cisplatin in a panel of ovarian cancer cell lines. Median-drug-effect analysis showed Nutlin-3 or RG7388 combination with cisplatin was additive to, or synergistic in a p53-dependent manner, resulting in increased p53 activation, cell cycle arrest and apoptosis, associated with increased p21 WAF1 protein and/or caspase-3/7 activity compared to cisplatin alone. Although MDM2 inhibition activated the expression of p53-dependent DNA repair genes, the growth inhibitory and pro-apoptotic effects of p53 dominated the response. These data indicate that combination treatment with MDM2 inhibitors and cisplatin has synergistic potential for the treatment of ovarian cancer, dependent on cell genotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · cited 1×
“The major benefits of combination therapy are the potential for a synergistic therapeutic effect, dose and toxicity reduction, and delay or prevention of drug resistance [24, 25].”
BackgroundChou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
p21 in cancer: Intricate networks and multiple activities
Abbas, T., & Dutta, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2657 · Cited by 2,712 · cited 1×
“Across the 3 cell lines, Nutlin-3/RG7388 increased CDKN1A and SESN1 expression consistent with their essential role in cell cycle arrest and growth inhibition [36, 37].”
Backgroundp53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling
Budanov, A. V., & Karin, M. (2008) · Cell · doi:10.1016/j.cell.2008.06.028 · Cited by 1,326 · cited 1×
“Across the 3 cell lines, Nutlin-3/RG7388 increased CDKN1A and SESN1 expression consistent with their essential role in cell cycle arrest and growth inhibition [36, 37].”
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279 · cited 1×
“It has been substantially established that p53 protects cells against environmental and intra-cellular stress stimuli by playing a central role in regulating cell cycle control, differentiation, proliferation, DNA repair and apoptosis (reviewed by [4]).”
BackgroundHaupt, S., Berger, M., Goldberg, Z., & Haupt, Y. (2003) · Journal of Cell Science · doi:10.1242/jcs.00739 · Cited by 1,136 · cited 3×
“A possible explanation for the lack of evidence of apoptosis in OAW42 might be high expression of antiapoptotic proteins such as BCL-2, BCL-X and MCL-1, or deficiency in downstream factors involved in the apoptosis cascade [27, 28].”
BackgroundShangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595 · cited 1×
“RG7388 was subsequently developed as a second generation MDM2 inhibitor with superior potency, selectivity and oral bioavailability suitable for clinical development to inhibit the MDM2-p53 interaction and activate the p53 pathway [7, 8].”
BackgroundTovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2807 · Cited by 283 · cited 1×
“RG7388 was subsequently developed as a second generation MDM2 inhibitor with superior potency, selectivity and oral bioavailability suitable for clinical development to inhibit the MDM2-p53 interaction and activate the p53 pathway [7, 8].”
BackgroundMDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin
Hu, B., Gilkes, D. M., Farooqi, B., Sebti, S. M., & Chen, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c600147200 · Cited by 236
Cited by
MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling
Venkatesh, D., O'Brien, N. A., Zandkarimi, F., Tong, D. R., Stokes, M. E., Dunn, D. E., Kengmana, E. S., Aron, A. T., Klein, A. M., Csuka, J. M., et al. (2020) · Genes & Development · doi:10.1101/gad.334219.119 · Cited by 274
Targeting Biomolecular Condensation and Protein Aggregation against Cancer
Silva, J. L., Foguel, D., Ferreira, V. F., Vieira, T. C. R. G., Marques, M. A., Ferretti, G. D. S., Outeiro, T. F., Cordeiro, Y., & de Oliveira, G. A. P. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00131 · Cited by 89
Development of selective small molecule MDM2 degraders based on nutlin
Wang, B., Wu, S., Liu, J., Yang, K., Xie, H., & Tang, W. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.046 · Cited by 77
Kocik, J., Machula, M., Wisniewska, A., Surmiak, E., Holak, T. A., & Skalniak, L. (2019) · Cancers · doi:10.3390/cancers11071014 · Cited by 46
“p53 activation, enhanced apoptosis and cell cycle arrest [34,37].”
BackgroundCui, Y., Zhou, J., & Rong, F. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.09.135 · Cited by 14
Metadata
- Authors
- Zanjirband, M., Edmondson, R. J., & Lunec, J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-05-20
- Volume
- 7
- Issue
- 26
- Pages
- 40115-40134
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2396526272
- Cited by
- 63
- References
- 12
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.